Promising avenues of therapeutics for bipolar illness.
Basic scientific advances in understanding the neuropsychobiology of bipolar disorder have given us a multitude of opportunities to explore and exploit new avenues of therapeutics. Pharmacotherapeutic approaches include: neuropeptides (agonists such as thyrotropin-releasing hormone and antagonists such as corticotropin-releasing hormone), neurotrophic factors (especially brain-derived neurotrophic factor), and glutamatergic mechanisms (such as riluzole, ketamine, and antagonists of the NR-2B subunit of the glutamate receptor). Physiological interventions that would offer alternatives to electroconvulsive therapy include: repeated transcranial magnetic stimulation, especially at more intense stimulation parameters; magnetic stimulation therapy (seizures induced more focally by magnetic rather than electrical stimulation with resulting reduced meaning loss); vagal nerve stimulation, and deep brain stimulation. However, these, as well as the panoply of existing treatments, require further intensive investigation to place each of them in the proper therapeutic sequence and combination for the individual patient, based on development of better clinical and biological predictors of response. Large clinical trial networks and development of systematic research in clinical practice settings, such as that featured by the National Cancer Institute for cancer chemotherapy, would greatly accelerate the progress in incorporating new, as well as existing, agents into the best treatment strategies. The bipolar disorders, which are increasingly recognized as complex, highly comorbid conditions with a high morbidity and mortality, of which the majority start in childhood and adolescence, are not likely to respond completely to any single new treatment agent, and new public health initiatives and research strategies are needed as much as any new single treatment advance.
Post
Robert M
RM
George Washington University School of Medicine, USA. robert.post@speakeasy.net
D000818:Animals; D001714:Bipolar Disorder / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000592:standards; D004195:Disease Models, Animal; D004599:Electric Stimulation Therapy / Q000379:methods / Q000639:trends; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009462:Neurology / Q000379:methods* / Q000639:trends; D009479:Neuropeptides / Q000494:pharmacology / Q000627:therapeutic use; D009480:Neuropharmacology / Q000379:methods* / Q000639:trends; D011570:Psychiatry / Q000379:methods* / Q000639:trends; D050781:Transcranial Magnetic Stimulation / Q000379:methods / Q000639:trends
D018691:Excitatory Amino Acid Antagonists; D009479:Neuropeptides